[1] SHAPIRO B, CHAKRABARTY M, COHN E M. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease, 1983
[2] 屠红, 高海峰, 傅士龙. 肿瘤患者循环DNA的定量研究. 中华肿瘤杂志2004(10)
[3] SIDRANSKY D. Nucleic acid-based methods for the detection of cancer. 1997. doi:10.1126/science.278.5340.1054
[4] SOZZI G, CONTE D, MARIANI L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. 2001
[5] DELIGEZER U, YAMAN F, ERTEN N. Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients. 2003(1-2). doi:10.1016/S0009-8981(3)00279-1
[6] LIU Y C, SUN J N, LIANG X B. Detection of serum DNA in cancer patients by modified methylation specific PCR. Chinese-German Journal of Clinical Oncology2002(3)
[7] ZOU H Z, YU B M, WANG Z W. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. 2002
[8] USADE H, BRABENDER J, DANENBERG K D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue,serum,and plasma DNA of patients with lung cancer. 2002(2)
[9] BROCK M V, GOU M, AKIYAMA Y. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. 2003(8)
[10] ZHANG L, LU W, MIAO X. Inactivation of DNA repair gene o6-methylguanine-DNA methytransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. 2003(6). doi:10.1093/carcin/bgg062
[11] SOZZI G, MUSSO K, RATCLIFFE C. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients:a prospect for early diagnosis, 1999
[12] 易斌, 杨和平, 阮志华. 肺癌患者血浆游离DNA微卫星检测的意义. 第三军医大学学报2003(5)
[13] SHAW J A, SMITH B A, WALSH T. Microsatellite alterations in plasma DNA of primary breast cancer patients, 2000
[14] TABACK B, FUJIWARA Y, WANG H J. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. 2001(15)
[15] 逄锦忠, 钦伦秀, 任宁. 肝细胞癌患者血浆循环DNA微卫星变异的研究. 中华医学杂志2006(24)
[16] GASTELLS A, PUIG P, MORA J. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma:diagnostic utility and prognostic significance. 1999(2)
[17] KOPRESKI M S, BENKO F A, BORYS D J. Somatic mutation screening:identification of individuals harboring K-ras mutations with the use of plasma DNA. 2000(11). doi:10.1093/jnci/92.11.918
[18] GOCKE C D, BEMKO F A, KOPRESKI M S. p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas, 2000
[19] GONZALEZ R, SILVA J M, SANCHEZ A. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients:follow-up study and prognostic significance. 2000(9). doi:10.1023/A:1008305412635
[20] SHAO Z M, WU J, SHEN Z Z. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. 2001(8)
[21] HUANG X H, SUN L H, LU D D. Codon 249 mutation in exon 7 of p53 gene in plasma DNA:maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area,China. World Journal of Gastroenterology2003(4)
[22] 邓立春, 姜藻, 何华. 荧光法检测外周血DNA对恶性肿瘤的诊断价值. 实用临床医药杂志2006(1). doi:10.3969/j.issn.1672-2353.2006.01.019
[23] MULCAHY H E, LYAUTEY J, LEDERREY C. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. 1998(2)
[24] SILVA J M, GARCIA J M, DOMINGGUEZ G. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. 2002(1). doi:10.1245/aso.2002.9.1.71
[25] SILVA J M, SILVA J, SANCHEZ A. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of diseases survival. 2002(12) |
